[ad_1]
The European Medicines Agency (EMA) has recommended for use in the European Union a vaccine against a new type of coronavirus developed by the pharmaceutical company Janssen Pharmaceutica-Cilag NV, part of the Johnson & Johnson group, in the European Union.
According to the EMA, the vaccine meets the requirements for efficacy, safety and quality. As has been written, research has been conducted in the United States, South Africa and Latin America with 44,000 people and the number of symptomatic infections among vaccine recipients has been reduced by 67%, which is the efficacy of the vaccine.
Side effects were typically mild or moderate and resolved within a few days without exception. The most common symptom was pain at the injection site, but headaches, fatigue, muscle aches, and nausea were also reported in some cases.
The U.S. Food and Drug Administration (FDA) approved Johnson in late February Y Emergency use of a one-component vaccine developed by Johnson to prevent new types of coronavirus disease. The single injection vaccine is 85% effective in preventing the development of serious Covid-19 complications caused by the SARS-CoV-2 virus, as evidenced by results of clinical trials on three continents.
The vaccine also prevented asymptomatic cases by 74 percent, which may suggest that the vaccine is suitable not only for preventing the disease but also for spreading it. No vaccinated patients died of Covid-19 during the study, so they provided complete protection against the fatal disease. The vaccine successfully prevented moderate disease in two-thirds of the cases. According to a previous analysis by the New York Times, this could cause fundamental changes in the return to normal daily life, since the spread of the infection is caused mainly by asymptomatic individuals. In the United States, people currently vaccinated with the Pfizer and Moderna vaccines are also not advised to stop wearing a mask or end their distance, that is, to return to a practically normal life. Also in this case, the Johnson and Johnson vaccination could be a breakthrough.
Johnson & Johnson had previously promised to administer 20 million doses by the end of March and a total of 100 million by the summer. The company promised to produce a billion doses before the end of the year, sooner.
Recently, however, the company announced that it would not be able to deliver the 55 million vaccines ordered by the European Commission that member states had expected in the second quarter. However, it is unclear how many batches they will eventually be able to produce.
Daily comment from Heléne Fritzon, Swedish MEP:
I think it is very important that everyone keep their commitments. I will pressure the European Commission to consider time as an important factor. It is about people’s lives, their health and their safety. The vaccine for Johnson and Johnson will be approved in a few days. This vaccine is highly anticipated in the Member States because it provides protection in a single dose, unlike the vaccines used so far, which require two injections.
Gergely Gulyás Minister in charge of the Prime Minister’s Office in today’s government information He said: Hungary has seized 4.3 million Johnson & Johnson single-dose vaccines.
(Cover image: SOPA Images / Getty Images Hungary)
[ad_2]
